Bethesda, MD (Might 14, 2021) — Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can present further vital weight reduction for sufferers who aren’t candidates for invasive weight-loss surgical procedure, in response to analysis that was chosen for presentation at Digestive Illness Week® (DDW) 2021.
“Because the worldwide weight problems fee continues to climb, so do the variety of folks searching for bariatric surgical procedure to deal with their situation,” stated Anna Carolina Hoff, MD, lead researcher on the examine and founder and medical director of Angioskope Brazil, São José dos Campos. “Surgical procedures are a number of the most profitable methods to assist sufferers drop some pounds, however they’ll ultimately include problems. Our examine exhibits that sufferers could not must bear invasive surgical procedure to get related outcomes.”
In a double-blind examine, researchers randomized 61 sufferers present process ESG into two teams with one group of 29 sufferers receiving semaglutide — an injectable glucagon-like peptide-1 receptor that has been identified to stimulate weight reduction — starting one month after the process. One other group of 29 sufferers obtained a placebo administered with look-alike injector pens. Three sufferers have been misplaced to follow-up. Members have been monitored every month for physique weight and physique composition, and blood panels have been taken each three months.
Sufferers who obtained semaglutide misplaced on common 26.7 p.c of their complete physique weight in comparison with the management group, which on common misplaced 19.6 p.c of complete physique weight. The semaglutide group misplaced 86.3 p.c of their extra weight — the quantity of weight the sufferers wanted to lose to succeed in regular BMI — in comparison with 60.4 p.c for the management group. The semaglutide group additionally misplaced 12.7 p.c of their physique fats by weight in comparison with 9 p.c for the management group. Lastly, glycated hemoglobin (Hb1Ac) ranges fell 0.95 for the semaglutide group and 0.61 for the controls.
Surgical procedures, equivalent to laparoscopic sleeve gastrectomy, include elevated prices and a better threat for problems, equivalent to gastroesophageal reflux illness, or GERD. These surgical procedures are usually restricted to these with a BMI of not less than 35 with comorbidities, or with a BMI above 40. ESG will be carried out at an earlier stage of the illness and at a decrease BMI, so extra sufferers can get the therapy they want earlier than their illness progresses. Treating sufferers with weight problems earlier will help scale back loss of life and comorbidities in addition to scale back prices related to therapies for these circumstances.
“ESG has been accessible to sufferers for years, but it surely has not at all times been as profitable as surgical choices in serving to sufferers drop some pounds,” stated Dr. Hoff. “We now have a minimally invasive process that may be simply as profitable when mixed with semaglutide and will be made accessible to much more folks seeking to lose a major quantity of weight.”
ESG is carried out by guiding a tool via the affected person’s throat and into the abdomen, the place an endoscopist makes use of sutures to make the abdomen smaller. This helps sufferers drop some pounds by limiting the quantity they’ll eat. Sufferers are candidates for ESG if they’ve a BMI at or above 30, and weight loss program and train haven’t helped them drop some pounds, or if they don’t seem to be a candidate for surgical procedure, or don’t want to pursue surgical procedure.
The researchers warning that long run sturdiness of the therapy nonetheless must be decided.
DDW Presentation Particulars
Dr. Hoff will current information from the examine, “Semaglutide in affiliation to endoscopic sleeve gastroplasty: Taking endoscopic bariatric procedures outcomes to the subsequent degree,” summary Su548, on Sunday, Might 23, at 12:15 p.m. EDT. For extra details about featured research, in addition to a schedule of availability for featured researchers, please go to http://www.
Digestive Illness Week® (DDW) is the biggest worldwide gathering of physicians, researchers and lecturers within the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure. Collectively sponsored by the American Affiliation for the Research of Liver Ailments (AASLD), the American Gastroenterological Affiliation (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgical procedure of the Alimentary Tract (SSAT), DDW is a totally digital assembly from Might 21-23, 2021. The assembly showcases greater than 2,000 abstracts and lots of of lectures on the newest advances in GI analysis, medication and expertise. Extra info will be discovered at http://www.
Disclaimer: AAAS and EurekAlert! aren’t accountable for the accuracy of stories releases posted to EurekAlert! by contributing establishments or for using any info via the EurekAlert system.